APOE and Alzheimer disease: The higher APOE ε4 carrier prevalence in LMCI (64.7%) compared to CN (12.5%) and EMCI (18.8%) supports genetic vulnerability, consistent with studies linking APOE ε4 to increased AD risk in genomic studies across the lifespan [57, 58, 59].